PROCEDES ET COMPOSITIONS UTILISABLES POUR LA DETECTION DE MUTATIONS AFFECTANT LE GENE CALR DANS LES MALADIES MYELOPROLIFERATIVES

METHODS AND COMPOSITIONS FOR THE DETECTION OF CALR MUTATIONS IN MYELOPROLIFERATIVE DISEASES

Abrégé français

La présente invention concerne des procédés et des compositions permettant la détection de mutations de lignée germinale par délétion dans le cadre, affectant le gène CALR. L'invention concerne également des procédés permettant d'établir le pronostic de maladies myéloprolifératives et la probabilité de développer des mutations somatiques dans des gènes impliqués dans la voie JAK-STAT.

Abrégé anglais

Provided herein are methods and compositions for the detection of in-frame deletion germline mutations in the CALR gene. Also provided are methods for determining the prognosis of myeloproliferative diseases and the likelihood of developing somatic mutations in genes involved in the JAK-STAT pathway.

Revendications

WHAT IS CLAIMED IS:
1. A method for detecting an in-frame deletion mutation (Indel) in exon 9
of the
calreticulin (CALR) gene comprising:
performing a nucleic acid detection assay on a patient sample to detect an
CALR exon 9 Indel mutation, wherein the mutation is selected from the group
consisting of
p.E381_ A382>A, p.D397_ D400>D, p.E405_ V409>V.
2. The method of claim 1, wherein the method comprises nucleic acid
amplification.
3. The method of any of claims 1-2, wherein the method comprises nucleic
acid
amplification using a primer pair, comprising a forward primer and a reverse
primer that
flank the deletion mutation.
4. The method of any of claims 1-3, wherein the method comprises polymerase
chain reaction (PCR), reverse transcription polymerase chain reaction (RT-
PCR), real-time
PCR (qPCR), or nested PCR.
5. The method of any of claims 1-4, wherein the method comprises using a
labeled oligonucleotide probe to detect the deletion mutation, wherein the
labeled probe is
specific for a nucleic acid having the deletion, and does not hybridize to a
wild type
sequence.
6. The method of claim 5, wherein the labeled probe comprises from about 10
to
30 consecutive nucleotides of the sequence SEQ ID NO: 1 and comprises the CALR
exon 9
deletion site.
7. The method of any of claims 1-6, wherein the method comprises sequencing
an amplicon comprising all or a portion of CALR exon 9 comprising the
deletion.
8. The method of any of claims 1-7, wherein the amplicon is detected using
a
labeled oligonucleotide probe.
-59-

9. The method of any of claims 1-8, wherein the nucleic acid is DNA, cDNA
genomic DNA or RNA.
10. The method of any of claims 1-9, wherein the patient sample is a blood,
serum, plasma, or biopsy sample.
11. The method of any of claims 1-10, wherein the patient has a
myeloproliferative disease or is suspected of having a myeloproliferative
disease.
12. The method of claim 11, wherein the myeloproliferative disease is
selected
from among polycythemia vera, essential thrombocythemia, idiopathic
myelofibrosis, and
unclassified myeloproliferative disease.
13. The method of any of claims 1-12, further comprising detecting one or
more
additional mutations in one or more additional genes associated with a
myeloproliferative
disease, wherein the one or more additional genes is a JAK-STAT pathway gene.
14. The method of claim 13, wherein the one or more additional genes is
JAK2,
MPL, CSFR3R, ASXL1, or ZRSR2.
15. The method of any of claims 13-14, wherein the one or more additional
mutations is selected from among a mutation in exon 12 or exon 14 of JAK2,
exon 10 of MPL
or exon 14 or exon 17 CSFR3R.
16. The method of any of claims 13-15, wherein the one or more additional
mutations is selected from among JAK2 V617F, MPL W515L, CSFR3R A470T, ASXL1
D954fs*26, or ZRSR2 S449_R450du.
17. A method for diagnosing a hematopoietic disease in a patient
comprising:
(a) performing a nucleic acid detection assay on a sample
comprising
CALR nucleic acid from a patient to determine whether the nucleic acid
comprises a CALR
exon 9 Indel mutation, wherein the mutation is selected from the group
consisting of
p.E381_A382>A, p.D397_D400>D, p.E405_V409>V; and
-60-

(b) diagnosing the patient as having a hematopoietic disease
when the
CALR exon 9 Indel mutation is detected.
18. The method of claim 16, wherein the method comprises nucleic acid
amplification.
19. The method of any of claims 17-18, wherein the method comprises nucleic
acid amplification using a primer pair, comprising a forward primer and a
reverse primer that
flank the deletion mutation.
20. The method of any of claims 17-19, wherein the method comprises
polymerase chain reaction (PCR), reverse transcription polymerase chain
reaction (RT-PCR),
real-time PCR (qPCR), or nested PCR.
21. The method of any of claims 17-20, wherein the method comprises using a
labeled oligonucleotide probe to detect the deletion mutation, wherein the
labeled probe is
specific for a nucleic acid having the deletion, and does not hybridize to a
wild type
sequence.
22. The method of claim 21, wherein labeled probe comprises from about 10
to 30
consecutive nucleotides of the sequence SEQ ID NO: 1 and comprises the CALR
exon 9
deletion site.
23. The method of any of claims 17-22, wherein the method comprises
sequencing
an amplicon comprising all or a portion of CALR exon 9 comprising the
deletion.
24. The method of any of claims 17-23, wherein the method comprises
detecting
an amplicon using a labeled oligonucleotide probe.
25. The method of any of claims 17-24, wherein the nucleic acid is DNA,
cDNA
genomic DNA or RNA.
26. The method of any of claims 17-25, wherein the patient sample is a
blood,
serum, or plasma, or biopsy sample.
-61-

27. The method of any of claims 17-26, wherein the hematopoietic disease is
a
myeloproliferative disease.
28. The method of any of claims 17-27, wherein the myeloproliferative
disease is
selected from among polycythemia vera, essential thrombocythemia, idiopathic
myelofibrosis, and unclassified myeloproliferative disease.
29. The method of any of claims 17-28, further comprising detecting one or
more
additional mutations in one or more additional genes associated with a
myeloproliferative
disease, wherein the one or more additional genes is a JAK-STAT pathway gene.
30. The method of any of claims 17-29, further comprising administering a
therapy to the patient.
31. The method of claim 30, wherein the therapy comprises phlebotomy,
platelet
apheresis, transfusion therapy, chemotherapy, radiation therapy, surgery,
biologic therapy,
targeted therapy, high-dose, or stem cell transplant.
32. The method of claim 30, wherein the therapy comprises administration of
arsenic trioxide, azacitidine, cyclophosphamide, cytarabine, dasatinib,
daunorubicin
hydrochloride, decitabine, doxorubicin hydrochloride, imatinib mesylate,
nilotinib,
ruxolitinib phosphate, and vincristine sulfate.
33. A method for determining the likelihood that a patient will develop a
mutation
in a JAK-STAT pathway gene, comprising:
(a) performing a nucleic acid detection assay on a sample comprising
CALR nucleic acid from a patient to determine whether the nucleic acid
comprises a CALR
exon 9 Indel mutation, wherein the mutation is selected from the group
consisting of
p.E381_A382>A, p.D397_D400>D, p.E405_V409>V; and
(b) diagnosing said individual as having an increased likelihood of
developing a mutation in a JAK-STAT pathway gene if the CALR exon 9 Indel
mutation is
detected.
-62-

34. The method of claim 33, wherein the mutation is selected from among a
mutation in exon 12 or exon 14 of JAK2, exon 10 of MPL or exon 14 or exon 17
CSFR3R.
35. The method of any of claims 33-34, wherein the one or more additional
mutations is selected from among JAK2 V617F, MPL W515L, CSFR3R A470T, ASXL1
D954fs*26, or ZRSR2 S449_R450du.
36. The method of any of claims 33-35, wherein the patient has a
myeloproliferative disease.
37. The method of claim 36, wherein the myeloproliferative disease is
selected
from among polycythemia vera, essential thrombocythemia, idiopathic
myelofibrosis, and
unclassified myeloproliferative disease.
38. A method for determining the prognosis of a patient having a
myeloproliferative disease, comprising:
(a) performing a nucleic acid detection assay on a sample comprising
CALR nucleic acid from a patient to determine whether the nucleic acid
comprises a CALR
exon 9 Indel mutation, wherein the mutation is selected from the group
consisting of
p.E381_A382>A, p.D397_D400>D, p.E405_V409>V; and
(b) diagnosing the patient as having a poor prognosis when the CALR exon
9 Indel mutation is detected.
39. The method of claim 38, wherein the myeloproliferative disease is
selected
from among polycythemia vera, essential thrombocythemia, idiopathic
myelofibrosis, and
unclassified myeloproliferative disease.
40. A kit comprising a primer or probe that is complementary to and
specifically
hybridizes to a target nucleic acid comprising a CALR exon 9 Indel mutation in
a nucleic acid
sample, wherein the mutation is selected from the group consisting of
p.E381_A382>A,
p.D397_D400>D, p.E405_V409>V.
-63-

41. The kit of claim 40, wherein the primer or probe comprises from about
10 to
30 consecutive nucleotides of the sequence SEQ ID NO: 1 and comprises the CALR
exon 9
deletion site.
42. The kit any of claims 40-41, wherein the primer or probe is labeled
with one
or more of a radioisotope, a fluorophore, a chromophore, a dye, an enzyme, or
time of flight
(TOF) carrier.
43. The kit of any of claims 40-42, wherein the primer or probe is
configured to
indicate hybridization or binding by polymerase chain reaction (PCR), reverse
transcription
PCR (RT- PCR), fluorescence resonance energy transfer (FRET),
chemiluminescence,
enzymatic signal amplification, electron dense particles, magnetic particles,
capacitance
coupling or mass spectrometry.
44. An oligonucleotide probe or primer comprising from about 10 to 30
consecutive nucleotides of the sequence SEQ ID NO: 1 and comprising the CALR
exon 9
deletion site.
-64-

Description

CA 02983820 2017-10-23
WO 2016/172505 PCT/US2016/028877
METHODS AND COMPOSITIONS FOR THE DETECTION OF CALR